Sign Out
Exemestane is indicated for the treatment of advanced breast cancer in women with natural or induced post-menopausal status whose disease has progressed following anti-oestrogen therapy. Patient selection should be based on positive oestrogen and/or progesterone receptor status, because efficacy has not been demonstrated when it is absent.
Exemestane is indicated for the adjuvant treatment of post-menopausal women with estrogen-receptor positive early breast cancer, following 2-3 years of initial adjuvant Tamoxifen therapy.
